|
Asciminib Clinical Trials
4 actively recruiting trials across 1 location
Also known as: ABL001
Pipeline
Phase 2: 3Phase 1/2: 1
Top Sponsors
- M.D. Anderson Cancer Center3
- Gruppo Italiano Malattie EMatologiche dell'Adulto1
Indications
- Cancer4
- Chronic Myeloid Leukemia2
- Chronic Myeloid Leukemia, BCR/ABL-Positive1
- Philadelphia Chromosome Positive1
- CML, Chronic Phase1
Houston, Texas3 trials
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
MD Anderson Cancer Center
Phase 1/2
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
MD Anderson Cancer Center
Phase 2
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
The University of Texas MD Anderson Cancer Center
Phase 2
Other1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.